



July 17, 2024

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza,  
C/1, Block G,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.:** Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 17, 2024 titled **"Zydus announces non-exclusive patent licensing agreement with Takeda for 'Vault®' (Vonoprazan) in India"**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878



## **Zydus announces non-exclusive patent licensing agreement with Takeda for ‘Vault®’ (Vonoprazan) in India**

- *Vonoprazan is a novel gastrointestinal drug and is a next generation treatment for gastro duodenal ulcer and GERD.*

*Ahmedabad, 17 July 2024*

Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) a discovery-driven global lifesciences company has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India. The drug will be marketed under the brand name of Vault® in India.

Under the terms of this agreement, Zydus will be marketing the drug in India. Gastroesophageal Reflux Disease (GERD) is quite prevalent condition affecting patients in India. The pooled prevalence of GERD in the Indian population is 15.6 % as per study published in Indian Journal of Gastroenterology, 2021, citing age, body mass index (BMI), diet, tea/coffee intake, tobacco, and alcohol consumption as risk factors<sup>1</sup>.

Zydus is a pioneer in providing innovative treatment options to manage GERD like Pantodac® (Pantoprazole), Happi® (Rabeprazole), and Ocid® (Omeprazole). Zydus was the first company to introduce Pantoprazole in India in 1999. The launch of Vault® (Vonoprazan) will provide clinicians a novel treatment option to manage GERD and other acid peptic disorders for the Indian population.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, “With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum. In keeping with our patient-centric approaches, we have been enabling access to newer treatment options and innovative healthcare solutions over nearly three decades. We are happy to add Vault® to our wide basket of gastro therapeutic products and widen our range of treatments for acid peptic disorders.”



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878

Vonoprazan has a novel mechanism of action and it inhibits the binding of potassium ions to H<sup>+</sup>K<sup>+</sup> ATPase (proton pump) in parietal cells in the stomach, thereby it suppresses basal and stimulated gastric acid secretion. Vonoprazan is approved in India by the DCGI for the treatment of adults with Reflux esophagitis and other Acid Peptic Disorders (APD).

**References:**

1. Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology, 06 Jan 2021, 40(2):209-219

**About Zydus:**

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 26,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Zydus has been actively discovering and developing New Chemical Entities (NCEs) novel biologicals, several biosimilars and vaccines as a part of its innovation pipeline. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. The group aspires to transform lives through path-breaking discoveries. For more details visit [www.zyduslife.com](http://www.zyduslife.com)



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878